Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
Dalbavancin, tested against 146 staphylococci, was more potent than other drugs tested, with an MIC at which 50% of staphylococci were inhibited of 0.03 microg/ml and an MIC at which 90% of staphylococci were inhibited of 0.06 microg/ml by microdilution. For all strains, MICs of vancomycin, linezolid, ranbezolid, oritavancin, daptomycin, and quinupristin-dalfopristin were </=4.0 microg/ml. Dalbavancin was bactericidal at four times the MIC against all six strains tested.
Lin
Gengrong
G
Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA.
Credito
Kim
K
Ednie
Lois M
LM
Appelbaum
Peter C
PC
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial; D024881:Drug Resistance, Bacterial; D006020:Glycopeptides / Q000494:pharmacology*; D007700:Kinetics; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects*; D017334:Teicoplanin / Q000031:analogs & derivatives; D020713:Vancomycin Resistance
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D017334:Teicoplanin; C469289:dalbavancin